More Articles

Stada launches generic Exforge following patent revocation Generics/News | Posted 19/04/2019

German generics producer Stada Arzneimittel announced on 20 March 2019 that it is set to launch a generic version of the antihypertensive Exforge (amlodipine/valsartan combination), following the r...

WHO releases Q&A on biosimilars evaluation Reports | Posted 12/04/2019

At the 17th Biosimilar Medicines Conference in The Netherlands, the World Health Organization (WHO) outlined a new Q&A document to assist with the regulatory evaluation of biosimilar products.

EC approval for adalimumab biosimilar Idacio Biosimilars/News | Posted 12/04/2019

Fresenius Kabi, the generics unit of German healthcare giant Fresenius, announced on 3 April 2019 that it had received European Commission (EC) approval for its adalimumab biosimilar Idacio (MSB114...

Efficacy and safety of bevacizumab biosimilar ABP 215 Biosimilars/Research | Posted 12/04/2019

Authors from the US and Europe report data from a phase III study comparing the clinical efficacy and safety of the bevacizumab biosimilar ABP 215 (Mvasi) with originator bevacizumab Avastin in pat...

Novo Nordisk granted exclusivity on GLP-1 agonist Victoza until 2023 Pharma News | Posted 12/04/2019

Novo Nordisk has announced a settlement with Teva Pharmaceuticals (Teva) giving the company at least four years before it has to compete with biosimilar versions of its diabetes injectable Victoza...

Key considerations for biosimilars in the US Biosimilars/Research | Posted 12/04/2019

Key considerations regarding biosimilars for payers in the US are discussed in a recent review [1]. The authors explore factors promoting the uptake of biosimilars, interchangeability and naming co...

US government advances five bills to increase generics competition Policies & Legislation | Posted 12/04/2019

The US House Energy & Commerce Committee’s Health Subcommittee has advanced five bills related to generic drug competition. The bills have not yet been passed but will each be considered by the...

Biocad advancing its non-originator biologicals in Russia Biosimilars/General | Posted 12/04/2019

Russian biotechnology company Biocad has started an eculizumab study and has also registered its non-originator biological (BCD 057) in Russia.